Bone and soft tissue sarcomas, tumors of the skinBone and soft tissue sarcomas, tumors of the skinСаркомы костей, мягких тканей и опухоли кожи2219-46142782-3687Publishing House ABV Press271ORTHOPAEDIC PATHOMORPHOLOGYОРТОПЕДИЧЕСКАЯ ПАТОМОРФОЛОГИЯPrimary bone tumorsПервичные злокачественные опухоли костей, современное состояние вопросаSolovievYu. N.СоловьевЮ. Н.
Russian Federation
BoulytchevaI. V.БулычеваИ. В.
Russian Federation
irena@boulytcheva.comN.N.. Blokhin Russian Cancer Research Center, Russian Academy of Medical SciencesРоссийский онкологический научный центр им. Н.Н. Блохина РАМНHospital No. 62, MoscowМосковская онкологическая больница № 621103201242576411012022Copyright ©; 2012, Soloviev Y.N., Boulytcheva I.V.Copyright ©; 2012, Соловьев Ю.Н., Булычева И.В.2012Soloviev Y.N., Boulytcheva I.V.Соловьев Ю.Н., Булычева И.В.https://creativecommons.org/licenses/by/4.0https://sarbon.abvpress.ru/jour/article/view/271

Primary malignant bone tumors are rare with an estimated frequency is about 1,5-2% of all malignant tumors. The diagnosis and management of these neoplasms require multidisciplinary team approach, which includes orthopaedic surgeons, radiologists, pathologists and oncologists. With this approach and modern treatment 5-year survival of osteosarcoma and Ewing’s sarcoma is 70 and 60% respectively. The major advancements over the past few years in orthopaedic pathology are molecular studies, including genetic and immunoperoxidase studies. Newer surgical techniques, minimally invasive surgical procedures, tumor chemotherapy, bisphosphonates are new advancements.

Первичные опухоли скелета достаточно редки и составляют 1,5-2% от всех встречающихся злокачественных опухолей человека, однако абсолютное число их неуклонно увеличивается. Диагностика данной группы заболеваний трудна, требует опыта, специальной подготовки и ультидисциплинарного подхода с участием хирурга-ортопеда, лучевого диагноста, патолога и онколога. Данный подход к проблеме позволяет увеличить 5-летнюю выживаемость при остеосаркоме до 70%, саркоме Юинга до 60%. В представленом обзоре суммированы последние достижения в лечении, а также новые данные в области молекулярной биологиии патогенеза наиболее часто встречающихся костных сарком.

osteosarcomachondrosarcomaEwing’s sarcomachordomaостеосаркомасаркома ЮингахондросаркомахордомаMitchell A., Scheithauer B.W, Unni K.K. et al. Chordoma and chondroid neoplasms of the spheno-occiput. A immunohistochemical study of 41 cases with prognostic and nosologic implications. Cancer. 1993, v. 72, No. 10, р. 2943-2949.Bovee J.V.M.G., Hogendoorn P.C.W Wunder J.S. et al. Cartilage tumors and bone development: molecular pathology and possible theraputic targets. Nat. Rev. Cancer. 2010, v. 10, р. 481-488.Ragland B.D., Bell W.C., Lopez R.R. et al. Cytogenetics and molecular biology of osteosarcoma. Lab. Invest. 2002, v. 82, р. 365-373.Longhi A., Erani C., De Paolois M. et al. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat. Rev. 2006, v. 32, р. 423-436.Gafney R., Unni K.K., Sim F.H. et al. Follow-up study of long-term survivous of osteosarcoma in the pre-chemotherapy era. Hum. Pathol. 2006, v. 37, р. 1009-1014.Paulussen M., Bielack S., Jurgens H. et al. Ewing’s sarcoma of the bone: EMSO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2009, v 20, p. 140-142.Folpe A.L., Goldblum J.R., Rubin B.P et al. Morpholpogic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am. J. Surg. Path. 2005, v. 29, р. 1025-1035.The Skeletal lesions Interobserver Correlation among Expert Diagnosicians (SLICED) Study Group. Reliability of histopathologic and radiologic grading of cartilaginous neoplasms in long bones. J. Bone Joint Surg. Am. 2007, v. 89, р. 2113-2123.Klein M.J., Siegal G.P Osteosarkoma: anatomic and histologic variants. Am. J. Clin. Pathol. 2006, v. 125, р. 555-581.Hoch B.L., Nielsen G.P, Liebsh N.G. et al. Base of skull Chordomas in children and adolescents; a clinicopathologic study of 73 cases. Am. J. Surg. Pathol. 2006, v. 30, No. 70, р. 811-818.Kyriakos M., Totty W.G., Lenke L.G. Giant vertebral notochordal rest: a lesion distinct from chordoma: discussion of an evolving concept. Am. J. Surg. Pathol. 2003, v. 27, No. 3, р. 396-406.Yamaguchi T, Suzuki S., Ishiiwa H. et al. Benign notochordal cell tumors: a comparative histological study of benign notochordal cell tumors, classic chordomas, and notochordal vestides of fetal intervertebral discs. Am. J. Surg. Pathol. 2004, v. 28, р. 756-761.Almefty K., Pravdenkova S., Colli B.O. et al. Chordoma and chondrosarcoma: similar, but quite different, skull base tumors. Cancer. 2007, v. 110, No. 11, р. 2457-2467.Fuchs B., Dickey I.D., Yaszemski M.J. et al. Operative management of sacral chordoma. J. Bone Joint Surg. Am. 2005, v. 87, No. 10, р. 2211-2216.O’Hara B.J., Paetau A., Miettinen M. Keratin subsets and monoclonal antibody HBME-1 in chordoma: immunohistochemical differential diagnosis between tumors simulating chordoma. Hum. Pathol. 1998, v. 29, No. 2, р. 119-126.Cho H.Y, Lee M., Takei H. et al. Immunohistochemical comparison of chordoma with chondrosarcoma, myxopapillary ependymoma, chordoid meningioma. Appl. Immunochistochem. Mol. Morphol. 2009, v. 17, No. 2, p. 131-138.Huse J.T, Pasha T.L., Zhang P.J. D2-40 functions as an effective chondroid marker distinguishing true chondroid tumors from choedoma. Acta Neuropathol. 2007, v. 113, No. 1, р. 87-94.Brooks J.J., Trojanowski J.Q., LiVolsi V.A. Chondroid chordoma: A low grade chondrosarcoma and its differential diagnosis. Curr. Top Pathol. 1989, v. 80, р. 165-181.Vujovic S., Henderson S., Presnau N. et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for choedomas. J. Pathol. 2006, v. 209, No. 2, р. 157-165.